{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:57:21Z","timestamp":1792727841649,"version":"4.5.0"},"reference-count":32,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019347","name":"Tistou and Charlotte Kerstan Stiftung","doi-asserted-by":"publisher","award":["FP4WP1"],"award-info":[{"award-number":["FP4WP1"]}],"id":[{"id":"10.13039\/501100019347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2025,6,30]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      <jats:italic>PDE6A<\/jats:italic>\n                      -associated retinitis pigmentosa (RP) is a rare inherited retinal disease leading to severe vision loss and blindness, with no available treatment. This study assessed the safety and vision outcomes of a gene therapy using an adeno-associated virus (AAV) vector encoding PDE6A (AAV8.hPDE6A).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In an open-label, non-randomised controlled phase I\/IIa trial, nine patients with biallelic\n                      <jats:italic>PDE6A<\/jats:italic>\n                      variants received a single subretinal injection of AAV8.hPDE6A. Doses were either 1.0\u00d710\u00b9\u2070 (n=6) or 5.0\u00d710\u00b9\u2070 (n=3) total vector genomes. Safety was the primary endpoint, assessed via clinical examinations, laboratory analyses and optical coherence tomography imaging. Secondary outcomes included changes in visual function, such as best corrected visual acuity (BCVA), contrast sensitivity, colour perception, dark adaptation thresholds, visual fields, patient-reported outcomes and chromatic pupil campimetry over 1 year.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean patient age was 40.1 years, with baseline BCVA ranging from 40 to 82 letters (0.9\u20130.1 logMAR). No systemic adverse events occurred, and most ocular events resolved without treatment. Persistent adverse events included small peripheral atrophic areas (n=2), disturbed colour discrimination (n=3), cataract (n=1), slight central retinal thinning (n=5) and moderate visual acuity loss (n=2, 1 in each dose group). BCVA, full-field stimulus thresholds and other visual function measures showed statistically non-significant changes, with a trend towards worsening of retinal sensitivity in the treated eyes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Subretinal gene therapy with AAV8.hPDE6A did not improve visual function over 1 year and posed risks, including central retinal thinning and visual acuity decline. This is in contrast to the safety and efficacy profile established in preclinical models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2024-326480","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T17:20:12Z","timestamp":1755537612000},"page":"173-179","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and vision outcomes of subretinal gene supplementation therapy in\n                    <i>PDE6A<\/i>\n                    -associated retinitis pigmentosa: a non-randomised controlled trial"],"prefix":"10.1136","volume":"110","clinical-trial-number":[{"clinical-trial-number":"nct04611503","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9325-5616","authenticated-orcid":false,"given":"Felix F","family":"Reichel","sequence":"first","affiliation":[{"name":"University Eye Hospital, Centre for Ophthalmology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Institute for Ophthalmic Research, Centre for Ophthalmology, Centre for Ophthalmology, University Hospital Tubingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Dominik","family":"Fischer","sequence":"additional","affiliation":[{"name":"University Eye Hospital, Centre for Ophthalmology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-911X","authenticated-orcid":false,"given":"Katarina","family":"Stingl","sequence":"additional","affiliation":[{"name":"University Eye Hospital, Centre for Ophthalmology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Centre for Rare Eye Diseases, University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-8681","authenticated-orcid":false,"given":"Laura","family":"Kuehlewein","sequence":"additional","affiliation":[{"name":"University Eye Hospital, Centre for Ophthalmology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3086-6425","authenticated-orcid":false,"given":"Immanuel","family":"Seitz","sequence":"additional","affiliation":[{"name":"University Eye Hospital, Centre for Ophthalmology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Institute for Ophthalmic Research, Centre for Ophthalmology, Centre for Ophthalmology, University Hospital Tubingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peters","sequence":"additional","affiliation":[{"name":"University Eye Hospital, Centre for Ophthalmology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Ziegler","sequence":"additional","affiliation":[{"name":"University Eye Hospital, Centre for Ophthalmology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Wilhelm","sequence":"additional","affiliation":[{"name":"University Eye Hospital, Centre for Ophthalmology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Kohl","sequence":"additional","affiliation":[{"name":"Molecular Genetics Laboratory, Institute for Ophthalmic Research, Centre for Ophthalmology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Weisschuh","sequence":"additional","affiliation":[{"name":"Institute for Ophthalmic Research, Centre for Ophthalmology, Centre for Ophthalmology, University Hospital Tubingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martus","sequence":"additional","affiliation":[{"name":"Institute of Clinical Epidemiology and Applied Biometrics, University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Seeliger","sequence":"additional","affiliation":[{"name":"Institute for Ophthalmic Research, Centre for Ophthalmology, Centre for Ophthalmology, University Hospital Tubingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"Muehlfriedel","sequence":"additional","affiliation":[{"name":"Institute for Ophthalmic Research, Centre for Ophthalmology, Centre for Ophthalmology, University Hospital Tubingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Paquet-Durand","sequence":"additional","affiliation":[{"name":"Institute for Ophthalmic Research, Centre for Ophthalmology, Centre for Ophthalmology, University Hospital Tubingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H","family":"Tsang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Ulrich","family":"Bartz-Schmidt","sequence":"additional","affiliation":[{"name":"University Eye Hospital, Centre for Ophthalmology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ueffing","sequence":"additional","affiliation":[{"name":"Institute for Ophthalmic Research, Centre for Ophthalmology, Centre for Ophthalmology, University Hospital Tubingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhart","family":"Zrenner","sequence":"additional","affiliation":[{"name":"University Eye Hospital, Centre for Ophthalmology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Biel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Center for Drug Research, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wissinger","sequence":"additional","affiliation":[{"name":"Institute for Ophthalmic Research, Centre for Ophthalmology, Centre for Ophthalmology, University Hospital Tubingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-9238","authenticated-orcid":false,"given":"Stylianos","family":"Michalakis","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"2026012202151223000_110.2.173.1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jamaophthalmol.2020.4206","article-title":"Clinical Phenotype and Course of PDE6A-Associated Retinitis Pigmentosa Disease, Characterized in Preparation for a Gene Supplementation Trial","volume":"138","author":"Kuehlewein","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"2026012202151223000_110.2.173.2","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.63.5.9","article-title":"Central Visual Function and Genotype-Phenotype Correlations in PDE6A-Associated Retinitis Pigmentosa","volume":"63","author":"Kuehlewein","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026012202151223000_110.2.173.3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/5584_2021_649","article-title":"Photoreceptor Phosphodiesterase (PDE6): Structure, Regulatory Mechanisms, and Implications for Treatment of Retinal Diseases","volume":"1371","author":"Cote","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"2026012202151223000_110.2.173.4","doi-asserted-by":"publisher","DOI":"10.1038\/ng1295-468"},{"key":"2026012202151223000_110.2.173.5","doi-asserted-by":"publisher","DOI":"10.1038\/ng0693-130"},{"key":"2026012202151223000_110.2.173.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2010.06.016"},{"key":"2026012202151223000_110.2.173.7","doi-asserted-by":"publisher","DOI":"10.1002\/HUMU.23903"},{"key":"2026012202151223000_110.2.173.8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jamaophthalmol.2018.6367","article-title":"Longitudinal Clinical Follow-up and Genetic Spectrum of Patients With Rod-Cone Dystrophy Associated With Mutations in PDE6A and PDE6B","volume":"137","author":"Khateb","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"2026012202151223000_110.2.173.9","doi-asserted-by":"publisher","DOI":"10.1002\/humu.24064"},{"key":"2026012202151223000_110.2.173.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24636-1","article-title":"Genetic epidemiology of inherited retinal diseases in a large patient cohort followed at a single center in Italy","volume":"12","author":"Karali","year":"2022","journal-title":"Sci Rep"},{"key":"2026012202151223000_110.2.173.11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-81093-y","article-title":"Genetic landscape of 6089 inherited retinal dystrophies affected cases in Spain and their therapeutic and extended epidemiological implications","volume":"11","author":"Perea-Romero","year":"2021","journal-title":"Sci Rep"},{"key":"2026012202151223000_110.2.173.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.04.008"},{"key":"2026012202151223000_110.2.173.13","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"The Lancet"},{"key":"2026012202151223000_110.2.173.14","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1089\/hum.2017.156","article-title":"Gene Therapy Successfully Delays Degeneration in a Mouse Model of PDE6A-Linked Retinitis Pigmentosa (RP43)","volume":"28","author":"Sch\u00f6n","year":"2017","journal-title":"Hum Gene Ther"},{"key":"2026012202151223000_110.2.173.15","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.155"},{"key":"2026012202151223000_110.2.173.16","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2017.00342","article-title":"Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa","volume":"11","author":"Mowat","year":"2017","journal-title":"Front Neurosci"},{"key":"2026012202151223000_110.2.173.17","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01327-07"},{"key":"2026012202151223000_110.2.173.18","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/eye.2017.158","article-title":"Technique of retinal gene therapy: delivery of viral vector into the subretinal space","volume":"31","author":"Xue","year":"2017","journal-title":"Eye (Lond)"},{"key":"2026012202151223000_110.2.173.19","first-page":"50","article-title":"A quantitative scoring technique for panel tests of color vision","volume":"29","author":"Vingrys","year":"1988","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026012202151223000_110.2.173.20","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.8.6.19","article-title":"Objective Measurement of Local Rod and Cone Function Using Gaze-Controlled Chromatic Pupil Campimetry in Healthy Subjects","volume":"8","author":"Kelbsch","year":"2019","journal-title":"Transl Vis Sci Technol"},{"key":"2026012202151223000_110.2.173.21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.9.11.9","article-title":"The RUSH2A Study: Best-Corrected Visual Acuity, Full-Field Electroretinography Amplitudes, and Full-Field Stimulus Thresholds at Baseline","volume":"9","author":"Birch","year":"2020","journal-title":"Trans Vis Sci Tech"},{"key":"2026012202151223000_110.2.173.22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/13816810.2018.1509354","article-title":"Structural disease progression in PDE6-associated autosomal recessive retinitis pigmentosa","volume":"39","author":"Takahashi","year":"2018","journal-title":"Ophthalmic Genet"},{"key":"2026012202151223000_110.2.173.23","first-page":"231","article-title":"Farnsworth\u2019s 28 hue test","volume":"66","author":"Roth","year":"1966","journal-title":"Bull Soc Ophtalmol Fr"},{"key":"2026012202151223000_110.2.173.24","unstructured":"Health CAfDaTi . Clinical review report: dexamethasone (ozurdex): (allergan inc.): indication: for the treatment of adult patients with diabetic macular edema who are pseudophakic [internet]. 2018. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539248\/"},{"key":"2026012202151223000_110.2.173.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100516","article-title":"Dose-Dependent Progression of Chorioretinal Atrophy at the Injection Site After Subretinal Injection of rAAV2\/8 in Nonhuman Primates","volume":"4","author":"Seitz","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"2026012202151223000_110.2.173.26","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0419-13.2013"},{"key":"2026012202151223000_110.2.173.27","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2562"},{"key":"2026012202151223000_110.2.173.28","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn327"},{"key":"2026012202151223000_110.2.173.29","first-page":"990","article-title":"Apoptotic photoreceptor degeneration in experimental retinal detachment","volume":"36","author":"Cook","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026012202151223000_110.2.173.30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0079-6123(01)31053-1","article-title":"Chapter 49 Experimental retinal detachment: a paradigm for understanding the effects of induced photoreceptor degeneration","volume":"2001","author":"Fisher","year":"2001","journal-title":"Progress in Brain Research: Elsevier"},{"key":"2026012202151223000_110.2.173.31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312818","article-title":"Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy","volume":"22","author":"Varin","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026012202151223000_110.2.173.32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jamaophthalmol.2018.6367","article-title":"Longitudinal Clinical Follow-up and Genetic Spectrum of Patients With Rod-Cone Dystrophy Associated With Mutations in PDE6A and PDE6B","volume":"137","author":"Khateb","year":"2019","journal-title":"JAMA Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2024-326480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:16:21Z","timestamp":1769076981000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2024-326480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1,22]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bjo-2024-326480"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2024-326480","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}